Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Expressing Human Epidermal Growth Factor Receptor-2 (HER-2)”

20 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 20 results

Large-scale testing (Phase 3)Looking for participantsNCT06340568
What this trial is testing

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

Who this might be right for
Endometrial Cancer
BioNTech SE 480
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06577376
What this trial is testing

A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction AdenocarcinomaExpressing Human Epidermal Growth Factor Receptor-2 (HER-2)Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past
Shanghai Runshi Pharmaceutical Technology Co., Ltd
Early research (Phase 1)Study completedNCT00647114
What this trial is testing

Test V930/V932 in Patients With Cancers Expressing Human Epidermal Growth Factor Receptor 2 (HER-2) and/or Carcinoembryonic Antigen (CEA)(V930-003)(COMPLETED)

Who this might be right for
Cancer
Merck Sharp & Dohme LLC 41
Early research (Phase 1)Looking for participantsNCT06115902
What this trial is testing

TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. 150
Early research (Phase 1)Looking for participantsNCT07137416
What this trial is testing

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast Carcinoma+13 more
National Cancer Institute (NCI) 36
Testing effectiveness (Phase 2)Study completedNCT03602079
What this trial is testing

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Who this might be right for
HER2-positive Breast CancerHER2 Gene MutationHER-2 Gene Amplification+41 more
Klus Pharma Inc. 49
Early research (Phase 1)Study completedNCT04147819
What this trial is testing

A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein

Who this might be right for
Cancers With HER2 Expression
Bayer 14
Large-scale testing (Phase 3)Looking for participantsNCT07431281
What this trial is testing

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Who this might be right for
Gastric CancerGastroesophageal Junction AdenocarcinomaEsophageal Cancer
AstraZeneca 2,130
Testing effectiveness (Phase 2)Ended earlyNCT03505710
What this trial is testing

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Daiichi Sankyo 181
Testing effectiveness (Phase 2)Looking for participantsNCT07498478
What this trial is testing

Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment

Who this might be right for
Breast Cancer
TransThera Sciences (Nanjing), Inc. 94
Testing effectiveness (Phase 2)Study completedNCT04205630
What this trial is testing

SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma

Who this might be right for
Endometrial Cancer
Byondis B.V. 64
Early research (Phase 1)Study completedNCT01730118
What this trial is testing

Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing

Who this might be right for
Breast NeoplasmsBreast CancerAdenocarcinomas+1 more
National Cancer Institute (NCI) 33
Large-scale testing (Phase 3)Looking for participantsNCT06989112
What this trial is testing

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Who this might be right for
Endometrial Cancer
AstraZeneca 600
Testing effectiveness (Phase 2)Study completedNCT01138384
What this trial is testing

Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
NCIC Clinical Trials Group 19
Testing effectiveness (Phase 2)UnknownNCT02632201
What this trial is testing

Immunotherapy Using Pluripotent Killer-Human Epidermal Growth Factor Receptor-2 (PIK-HER2) Cells for the Treatment of Advanced Gastric Cancer With Liver Metastasis

Who this might be right for
Liver MetastasisGastric Cancer
Second Military Medical University 40
Testing effectiveness (Phase 2)Study completedNCT00284180
What this trial is testing

Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer

Who this might be right for
Breast NeoplasmsBreast Cancer
SCRI Development Innovations, LLC 32
Testing effectiveness (Phase 2)Study completedNCT03384940
What this trial is testing

DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)

Who this might be right for
Colorectal Neoplasm
Daiichi Sankyo Co., Ltd. 86
Early research (Phase 1)Study completedNCT03523572
What this trial is testing

Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer

Who this might be right for
Breast CancerUrothelial Carcinoma
Daiichi Sankyo 86
Testing effectiveness (Phase 2)Study completedNCT03329690
What this trial is testing

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]

Who this might be right for
Neoplasm, Gastrointestinal
Daiichi Sankyo Co., Ltd. 233
Testing effectiveness (Phase 2)Active Not RecruitingNCT06590857
What this trial is testing

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

Who this might be right for
Metastatic Breast CancerHER2-negative Breast CancerER+ Breast Cancer+1 more
RayzeBio, Inc. 16
252